RDY News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RD

Mkt Cap

$10.88B

Volume

2.29M

Next Earnings

October 23rd

Loading chart

RD

RDYDr. Reddy's Laboratories Limited American Depositary Shares

RDY

Pay with—

Available Balance0.00

RD

Mkt Cap

$10.75B

Volume

2.29M

Next Earnings

October 23rd

Chart Earnings News About Dividends Insider Filings

Top Stock Reports for Oracle, American Express & ProgressiveZacks analysts published research on 16 major stocks on October 12, 2026. Oracle faces headwinds from negative free cash flow and intense cloud competition but benefits from AI demand. American Express shows strong spending and customer acquisition despite rising expenses. Progressive maintains a neutral stance due to normalizing auto pricing and valuation concerns. Additional coverage includes Western Midstream, BrightSpring Health, and Dr. Reddy's Laboratories.Zacks Investment Research · Oct 12, 2026

Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive GrowthThe global substance use disorder treatment market is projected to grow from $11.6 billion in 2025 to $14.6 billion by 2030, with a compound annual growth rate of 4.6%. Growth is driven by long-acting therapies, telemedicine expansion, drug innovation, and increased government interventions, though challenges include low treatment penetration and stigma.GlobeNewswire Inc. · Oct 2, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDYPomerantz LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's announcement of weak Q1 FY2027 earnings with only $0.06 EPS, attributed to a ₹2.4 billion provision for out-of-specification semaglutide batches. The disclosure triggered a 9.4% stock price decline on July 22, 2026.GlobeNewswire Inc. · Sep 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSPomerantz LLP announced investigations into potential securities fraud at Emergent BioSolutions, Klarna Group, and Dr. Reddy's Laboratories. Emergent reported a $191.3 million impairment charge on its NARCAN asset group and cut full-year revenue guidance by 10.8%, citing increased competitive intensity. The stock fell 29.58% on the news.GlobeNewswire Inc. · Sep 23, 2026

Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's LaboratoriesThe global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.GlobeNewswire Inc. · Aug 31, 2026

DR. REDDY’S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudLaw firm Kirby McInerney LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's disclosure of a ₹2.4 billion provision for out-of-spec semaglutide batches in Q1 FY2027 earnings. The stock fell 9% on the news, though management stated there was no patient safety impact or regulatory filing impact.GlobeNewswire Inc. · Aug 6, 2026

Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease TherapiesThe global antiparasitic drugs market is projected to grow from USD 23.30 billion in 2026 to USD 30.98 billion by 2032 at a 4.88% CAGR. Growth is driven by persistent parasitic disease burden, drug resistance, climate-sensitive vector transmission, and public health programs. Key opportunities include resistance-ready combination therapies, pediatric formulations, AI-enabled discovery, and diagnostics-linked prescribing, with Africa and Asia-Pacific leading endemic demand.GlobeNewswire Inc. · Jul 20, 2026

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)The global generic drug market is projected to grow from USD 491.35 billion in 2024 to USD 926.54 billion by 2034, expanding at a CAGR of 6.55%. Growth is driven by increasing demand for cost-effective medicines, rising chronic diseases, and aging populations, particularly in North America and Asia-Pacific regions. However, the market faces challenges from low awareness, branded drug preference among practitioners, and limited rural distribution.GlobeNewswire Inc. · Jun 9, 2026

India's Generic Wave Hits Ozempic And Wegovy As Prices Drop SharplyFollowing the expiration of India's semaglutide patent, over 40 Indian pharmaceutical companies have launched generic versions of Novo Nordisk's Ozempic and Wegovy at dramatically reduced prices—approximately 70% cheaper than originals. Major players like Sun Pharmaceutical, Dr. Reddy's Laboratories, and Zydus Lifesciences are offering monthly treatments ranging from $7.99 to $44.73, with plans to expand into global markets including Canada, Brazil, and Latin America as the obesity market is projected to reach $100 billion by decade's end.Benzinga · Mar 23, 2026

Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute AnalyticaThe global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.GlobeNewswire Inc. · Feb 10, 2026

to start trading

RD

RDYDr. Reddy's Laboratories Limited American Depositary Shares

RDY

Pay with—

Available Balance0.00

Your PositionYou don't own any RDY yet.

Related Tickers

Earnings

Dividends

Last · Jul 24Annual

Amount$0.0834

Yield1.13%

Annual$0.15